Instill Science

A place to discuss science, share work, and find mentors and collaborators

Instill Science / post-9MesE8tl
May 19, 2023jessica-sacher
Biotech news Clinical Trial Phage therapy Phages and cancer

Copenhagen-based SNIPR Biome, a CARB-X portfolio company, has developed SNIPR001, a cocktail of CRISPR-armed phages designed to target E. coli. A recent release by Robin Berghaus of CARB-X highlights the potential of SNIPR001 to prevent bloodstream infections in cancer patients without disrupting their microbiomes.

Loading ...
No comments yet. Be the first to comment!